DIASights from Roche

This series is brought to you by Roche. We are committed to providing you with educational content, from key opinion leaders, related to personalized diagnostics. We aim to ensure on ongoing conversation is taking place in this evolving area of healthcare. Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Latest Talk

September 14, 2023 3:00pm Z | 56 mins

Tumor Area Positivity (TAP): a novel scoring algorithm for PD-L1 assessment

Immunohistochemistry assessment of PD-L1 protein expression levels in the tumor microenvironment is critical for identifying patients eligible for immunotherapy. Currently, different scoring approaches are used to assess tumor cell and immune cell staining with each approach having unique challenges. This talk presents the Tumor Area Positivity (TAP) score, a simple, visual-based estimate scoring algorithm that…

Watch now

On-demand Talks

Tumor Area Positivity (TAP): a novel scoring algorithm for PD-L1 assessment

1 week ago 56 mins
HER2-Low: a new category of patients who benefit from HER2-targeted therapy

2 months ago 52 mins
Unlocking the future of digital pathology: open environment is the Key!

4 months ago 86 mins
PathAI PD-L1(28-8)integration on Roche navify Digital Pathology open environment

4 months ago 59 mins
HER2 Testing: Towards a Brighter Future

6 months ago 75 mins
固形がんにおけるDNAミスマッチ修復(MMR) 機能異常とその臨床的意義〜IHC検査とがん免疫療法の臨床事例を踏まえて〜

11 months ago 62 mins
Cost effectiveness analysis of PD-L1 testing in NSCLC - IVD vs LDT

11 months ago 45 mins
Immunohistochemistry detection of DNA mismatch repair in colorectal cancer

1 year ago 44 mins

Latest Talk

Tumor Area Positivity (TAP): a novel scoring algorithm for PD-L1 assessment

On-demand Talks

Brighttalk site footer content